Eastman Kodak Co. saw its shares climb 4.7% Monday following the announcement that it has added four regulated pharmaceutical products to its portfolio, strengthening its footprint in laboratory and biopharmaceutical supplies.
The Rochester, New York-based company introduced two new formulations of Phosphate Buffered Saline (PBS) plus two Water for Injection (WFI) products. The firm said all four items are produced in the United States and are immediately orderable by research laboratories, biopharma developers and contract development and manufacturing organizations (CDMOs).
Kodak framed the launches as an extension of its existing unregulated key starting materials business and described the move as "a milestone" in the company’s long-term strategic plan. The two PBS formulations will join a standard PBS product the company already ships, while the WFI products represent Kodak’s first entries into that product category.
"In addition to legendary Kodak quality, customers will benefit from the dependability of U.S. manufacturing and the ability to get exactly the formulation and volume they need," said Jim Continenza, Kodak’s Executive Chairman and CEO.
The company highlighted that the new lines are manufactured in a cGMP-compliant production facility in Rochester. Kodak said the site includes sustainability-oriented features such as energy-efficient lighting, custom process equipment intended to reduce greenhouse gas emissions, and a water sterilization system designed to minimize consumption and waste.
Kodak noted it has supplied unregulated key starting materials to premier U.S. and multinational CDMOs for decades, and that it maintains more than 1,400 customer-ready processes for specialty chemicals. The company also stated it is pursuing ISO 13485 certification for medical device quality management systems.
For market participants, the product introductions signal Kodak’s push to move further into regulated pharmaceutical inputs while leveraging existing process capabilities and U.S. manufacturing capacity. Availability of the new PBS and WFI products was presented as immediate, with Kodak positioning the offerings to meet formulation and volume needs for a range of laboratory and biopharma customers.